IL110581A0 - Insulin formulation - Google Patents
Insulin formulationInfo
- Publication number
- IL110581A0 IL110581A0 IL11058194A IL11058194A IL110581A0 IL 110581 A0 IL110581 A0 IL 110581A0 IL 11058194 A IL11058194 A IL 11058194A IL 11058194 A IL11058194 A IL 11058194A IL 110581 A0 IL110581 A0 IL 110581A0
- Authority
- IL
- Israel
- Prior art keywords
- insulin
- formulation
- zinc
- total
- present
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 12
- 238000009472 formulation Methods 0.000 title abstract 7
- 239000000203 mixture Substances 0.000 title abstract 7
- 102000004877 Insulin Human genes 0.000 title abstract 6
- 108090001061 Insulin Proteins 0.000 title abstract 6
- 229940125396 insulin Drugs 0.000 title abstract 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 2
- 239000011701 zinc Substances 0.000 abstract 2
- 229910052725 zinc Inorganic materials 0.000 abstract 2
- 101000976075 Homo sapiens Insulin Proteins 0.000 abstract 1
- 102000007327 Protamines Human genes 0.000 abstract 1
- 108010007568 Protamines Proteins 0.000 abstract 1
- 239000013078 crystal Substances 0.000 abstract 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
- 230000005923 long-lasting effect Effects 0.000 abstract 1
- 229940048914 protamine Drugs 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/106,106 US5534488A (en) | 1993-08-13 | 1993-08-13 | Insulin formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL110581A0 true IL110581A0 (en) | 1994-11-11 |
Family
ID=22309529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL11058194A IL110581A0 (en) | 1993-08-13 | 1994-08-08 | Insulin formulation |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US5534488A (pl) |
| EP (1) | EP0646379B1 (pl) |
| JP (1) | JPH07149660A (pl) |
| KR (1) | KR950005324A (pl) |
| CN (1) | CN1109364A (pl) |
| AT (1) | ATE207761T1 (pl) |
| AU (1) | AU674975B2 (pl) |
| BR (1) | BR9403204A (pl) |
| CA (1) | CA2129763A1 (pl) |
| CO (1) | CO4230235A1 (pl) |
| CZ (1) | CZ193794A3 (pl) |
| DE (1) | DE69428860T2 (pl) |
| DK (1) | DK0646379T3 (pl) |
| ES (1) | ES2164691T3 (pl) |
| HU (1) | HUT67853A (pl) |
| IL (1) | IL110581A0 (pl) |
| NO (1) | NO942959L (pl) |
| NZ (1) | NZ264197A (pl) |
| PE (1) | PE14495A1 (pl) |
| PH (1) | PH30757A (pl) |
| PL (1) | PL177002B1 (pl) |
| PT (1) | PT646379E (pl) |
| RU (1) | RU2135205C1 (pl) |
| TW (1) | TW326394B (pl) |
| UA (1) | UA27874C2 (pl) |
| YU (1) | YU50494A (pl) |
| ZA (1) | ZA945939B (pl) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5578238A (en) * | 1992-10-30 | 1996-11-26 | Lord Corporation | Magnetorheological materials utilizing surface-modified particles |
| AR002976A1 (es) * | 1995-03-31 | 1998-05-27 | Lilly Co Eli | Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas |
| EP1396272A1 (en) * | 1997-12-23 | 2004-03-10 | Eli Lilly & Company | Insoluble Insulin Compositions for Controlling Blood Glucose |
| CO4970787A1 (es) * | 1997-12-23 | 2000-11-07 | Lilly Co Eli | Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea |
| US6956021B1 (en) * | 1998-08-25 | 2005-10-18 | Advanced Inhalation Research, Inc. | Stable spray-dried protein formulations |
| EP1196446A1 (en) * | 1999-06-29 | 2002-04-17 | Eli Lilly And Company | Protamine-free insoluble acylated insulin compositions |
| US7678364B2 (en) | 1999-08-25 | 2010-03-16 | Alkermes, Inc. | Particles for inhalation having sustained release properties |
| AU4935701A (en) * | 2000-03-24 | 2001-10-08 | Genentech Inc | Use of insulin for the treatment of cartilagenous disorders |
| WO2003057650A2 (en) | 2002-01-09 | 2003-07-17 | Emisphere Technologies, Inc. | Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate |
| WO2002029833A1 (en) * | 2000-10-06 | 2002-04-11 | The Adviser - Defence Research & Development Organisation | A magneto sensitive fluid composition and a process for preparation thereof |
| US6875368B2 (en) * | 2000-11-29 | 2005-04-05 | The Adviser Defence Research And Development Organisation, Ministry Of Defence, Government Of India | Magnetorheological fluid composition and a process for preparation thereof |
| DE60217066T4 (de) * | 2001-02-09 | 2010-07-01 | Genentech, Inc., South San Francisco | Kristallisierung von igf-1 |
| DE10114178A1 (de) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
| DE10227232A1 (de) * | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
| RU2251426C1 (ru) * | 2003-09-18 | 2005-05-10 | Цыганков Владимир Владимирович | Способ получения инсулина из природного источника и инсулин |
| EP1711220A1 (en) * | 2004-01-16 | 2006-10-18 | Biodel, Inc. | Sublingual drug delivery device |
| US20080096800A1 (en) * | 2004-03-12 | 2008-04-24 | Biodel, Inc. | Rapid mucosal gel or film insulin compositions |
| US20080090753A1 (en) | 2004-03-12 | 2008-04-17 | Biodel, Inc. | Rapid Acting Injectable Insulin Compositions |
| EP2106790B1 (en) * | 2004-03-12 | 2012-10-24 | Biodel, Inc. | Rapid acting drug delivery compositions |
| US20080248999A1 (en) * | 2007-04-04 | 2008-10-09 | Biodel Inc. | Amylin formulations |
| US20080085298A1 (en) * | 2004-03-12 | 2008-04-10 | Biodel, Inc. | Rapid Mucosal Gel or Film Insulin Compositions |
| JP4903690B2 (ja) | 2004-05-06 | 2012-03-28 | エミスフェアー・テクノロジーズ・インク | Ｎ−［８−（２−ヒドリキシベンゾイル）アミノ］カプリル酸一ナトリウムの結晶多形体 |
| AU2005249410A1 (en) * | 2004-05-14 | 2005-12-15 | Emisphere Technologies, Inc. | Aryl ketone compounds and compositions for delivering active agents |
| CN101027318B (zh) | 2004-07-19 | 2016-05-25 | 比奥孔有限公司 | 胰岛素-低聚物共轭物，制剂及其用途 |
| AU2005271526B2 (en) * | 2004-08-03 | 2011-12-08 | Emisphere Technologies, Inc. | Antidiabetic oral insulin-biguanide combination |
| US20060078623A1 (en) * | 2004-08-13 | 2006-04-13 | Emisphere Technologies, Inc. | Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent |
| RU2288000C1 (ru) * | 2005-04-27 | 2006-11-27 | Институт нефтехимического синтеза им. А.В. Топчиева РАН (ИНХС РАН) | Раствор инсулина для перорального введения |
| US8084420B2 (en) * | 2005-09-29 | 2011-12-27 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
| US7713929B2 (en) * | 2006-04-12 | 2010-05-11 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
| WO2007121256A2 (en) * | 2006-04-12 | 2007-10-25 | Biodel, Inc. | Rapid acting and long acting insulin combination formulations |
| ES2579229T3 (es) | 2007-03-13 | 2016-08-08 | Jds Therapeutics, Llc | Procedimientos y composiciones para la liberación sostenida de cromo |
| WO2009002867A2 (en) | 2007-06-26 | 2008-12-31 | Nutrition 21, Inc. | Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement |
| US9241908B2 (en) | 2007-10-16 | 2016-01-26 | Biocon Limited | Orally administrable solid pharmaceutical composition and a process thereof |
| WO2009089181A1 (en) * | 2008-01-04 | 2009-07-16 | Blodel, Inc. | Insulin formulations for insulin release as a function of tissue glucose levels |
| PT3228320T (pt) | 2008-10-17 | 2020-03-26 | Sanofi Aventis Deutschland | Combinação de uma insulina e de um agonista do glp-1 |
| US9060927B2 (en) * | 2009-03-03 | 2015-06-23 | Biodel Inc. | Insulin formulations for rapid uptake |
| PH12011502708B1 (en) | 2009-07-06 | 2017-11-10 | Sanofi Aventis Deutschland | Insulin preparations containing methionine |
| JP5832439B2 (ja) | 2009-11-13 | 2015-12-16 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Ｇｌｐ−１アゴニスト、インスリン及びメチオニンを含む薬学的組成物 |
| SG10201500871TA (en) | 2009-11-13 | 2015-04-29 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a glp-1 agonist and methionine |
| BR112012020481A2 (pt) * | 2010-02-22 | 2017-01-10 | Univ Case Western Reserve | método para tratar um paciente, o método compreendendo administrar uma formulação farmacêutica contendo uma quantidade fisiologicamente efetiva de um análogo de insulina ou um sal fisiologicamente. |
| CN103179978A (zh) | 2010-08-30 | 2013-06-26 | 赛诺菲-安万特德国有限公司 | Ave0010用于制造供治疗2型糖尿病用的药物的用途 |
| AU2012223282B2 (en) | 2011-03-01 | 2017-02-02 | Nutrition 21, Llc | Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| CN107206058A (zh) | 2014-12-12 | 2017-09-26 | 赛诺菲-安万特德国有限公司 | 甘精胰岛素/利西拉来固定比率配制剂 |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| AU2017217466A1 (en) | 2016-02-11 | 2018-08-23 | Nutrition 21, Llc | Chromium containing compositions for improving health and fitness |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2626228A (en) * | 1945-05-17 | 1953-01-20 | Novo Terapeutisk Labor As | Method of producing crystalline insulin |
| US2882202A (en) * | 1950-04-05 | 1959-04-14 | Novo Terapeutisk Labor As | Insulin crystal preparations and methods of producing them |
| US2882203A (en) * | 1951-06-26 | 1959-04-14 | Novo Terapeutisk Labor As | Injectable insulin preparation with protracted effect |
| US2849370A (en) * | 1953-06-04 | 1958-08-26 | Novo Terapeutisk Labortorium A | Injectable insulin preparations with protracted effect and process of producing same |
| US3102077A (en) * | 1953-08-19 | 1963-08-27 | Christensen Henry Marinus | Preparation of insulin containing 2.75 to 8 percent zinc content |
| US2819999A (en) * | 1953-11-13 | 1958-01-14 | Novo Terapeutisk Labor As | Process for crystallization of insulin using freeze dried insulin as seeding material |
| US2799622A (en) * | 1953-11-14 | 1957-07-16 | Novo Terapeutisk Labor As | Process of producing insulin crystals of substantially uniform size and compositions thereof |
| US3060093A (en) * | 1957-07-18 | 1962-10-23 | Nordisk Insulinlab | Slowly acting insulin preparation in crystalline form and method of preparation |
| DE2933946A1 (de) * | 1979-08-22 | 1981-03-12 | Hoechst Ag, 6000 Frankfurt | Insulinkristallsuspension und verfahren zu ihrer herstellung. |
| DE3101382A1 (de) * | 1981-01-17 | 1982-09-02 | Hoechst Ag, 6000 Frankfurt | "verfahren zur herstellung von humanisulin oder dessen derivaten aus schweineinsulin oder dessen derivaten" |
| FI78616C (fi) * | 1982-02-05 | 1989-09-11 | Novo Industri As | Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt. |
| SU1131507A1 (ru) * | 1982-05-28 | 1984-12-30 | Черновицкий Ордена Трудового Красного Знамени Государственный Университет | Способ получени инсулина |
| DE3511269A1 (de) * | 1985-04-12 | 1986-10-09 | Veb Berlin-Chemie, Ddr 1199 Berlin | Verfahren zur reinigung von insulin |
| PH23446A (en) * | 1986-10-20 | 1989-08-07 | Novo Industri As | Peptide preparations |
| DE3827533A1 (de) * | 1988-08-13 | 1990-02-15 | Hoechst Ag | Pharmazeutische zubereitung zur behandlung des diabetes mellitus |
-
1993
- 1993-08-13 US US08/106,106 patent/US5534488A/en not_active Expired - Fee Related
-
1994
- 1994-08-04 HU HU9402287A patent/HUT67853A/hu unknown
- 1994-08-08 NZ NZ264197A patent/NZ264197A/en unknown
- 1994-08-08 IL IL11058194A patent/IL110581A0/xx not_active IP Right Cessation
- 1994-08-08 PE PE1994248043A patent/PE14495A1/es not_active Application Discontinuation
- 1994-08-08 ZA ZA945939A patent/ZA945939B/xx unknown
- 1994-08-08 BR BR9403204A patent/BR9403204A/pt not_active Application Discontinuation
- 1994-08-09 UA UA94085696A patent/UA27874C2/uk unknown
- 1994-08-09 DK DK94305883T patent/DK0646379T3/da active
- 1994-08-09 CA CA002129763A patent/CA2129763A1/en not_active Abandoned
- 1994-08-09 EP EP94305883A patent/EP0646379B1/en not_active Expired - Lifetime
- 1994-08-09 RU RU94028671A patent/RU2135205C1/ru active
- 1994-08-09 TW TW083107259A patent/TW326394B/zh active
- 1994-08-09 PT PT94305883T patent/PT646379E/pt unknown
- 1994-08-09 AT AT94305883T patent/ATE207761T1/de not_active IP Right Cessation
- 1994-08-09 PL PL94304600A patent/PL177002B1/pl unknown
- 1994-08-09 NO NO942959A patent/NO942959L/no not_active Application Discontinuation
- 1994-08-09 CO CO94035010A patent/CO4230235A1/es unknown
- 1994-08-09 KR KR1019940019550A patent/KR950005324A/ko not_active Abandoned
- 1994-08-09 PH PH48764A patent/PH30757A/en unknown
- 1994-08-09 DE DE69428860T patent/DE69428860T2/de not_active Expired - Fee Related
- 1994-08-09 ES ES94305883T patent/ES2164691T3/es not_active Expired - Lifetime
- 1994-08-10 CN CN94109082A patent/CN1109364A/zh active Pending
- 1994-08-10 CZ CZ941937A patent/CZ193794A3/cs unknown
- 1994-08-10 YU YU50494A patent/YU50494A/sh unknown
- 1994-08-10 JP JP6188204A patent/JPH07149660A/ja not_active Withdrawn
- 1994-08-12 AU AU70247/94A patent/AU674975B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| TW326394B (en) | 1998-02-11 |
| NO942959L (no) | 1995-02-14 |
| CA2129763A1 (en) | 1995-02-14 |
| YU50494A (sh) | 1997-01-08 |
| DE69428860D1 (de) | 2001-12-06 |
| ZA945939B (en) | 1996-02-08 |
| NO942959D0 (no) | 1994-08-09 |
| PT646379E (pt) | 2002-03-28 |
| NZ264197A (en) | 1997-01-29 |
| CO4230235A1 (es) | 1995-10-19 |
| PL177002B1 (pl) | 1999-09-30 |
| AU7024794A (en) | 1995-02-23 |
| CZ193794A3 (en) | 1995-03-15 |
| UA27874C2 (uk) | 2000-10-16 |
| PL304600A1 (en) | 1995-02-20 |
| JPH07149660A (ja) | 1995-06-13 |
| EP0646379B1 (en) | 2001-10-31 |
| PE14495A1 (es) | 1995-06-02 |
| KR950005324A (ko) | 1995-03-20 |
| HUT67853A (en) | 1995-05-29 |
| US5534488A (en) | 1996-07-09 |
| BR9403204A (pt) | 1995-04-18 |
| DK0646379T3 (da) | 2001-12-03 |
| AU674975B2 (en) | 1997-01-16 |
| PH30757A (en) | 1997-10-17 |
| ATE207761T1 (de) | 2001-11-15 |
| HU9402287D0 (en) | 1994-09-28 |
| EP0646379A1 (en) | 1995-04-05 |
| CN1109364A (zh) | 1995-10-04 |
| ES2164691T3 (es) | 2002-03-01 |
| RU2135205C1 (ru) | 1999-08-27 |
| DE69428860T2 (de) | 2002-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU9402287D0 (en) | Insulin formulation | |
| AU610636B2 (en) | Stabilised human protein preparations | |
| AU5707294A (en) | 3,3 diphenyl prop-2-yl amino acid derivatives and their use as tachykinin antagonists | |
| IL72494A (en) | Homologues of aprotinin with other aminoacids in position 15,instead of lysine,their preparation and pharmaceutical compositions containing them | |
| GB9108652D0 (en) | Immunoreactive compounds | |
| WO1995013297A3 (en) | Improved immunogenic compositions against human gastrin 17 | |
| AU3617689A (en) | Compositions containing chlorine dioxide and their preparation | |
| WO1994001006A3 (en) | Composition for use as a food or food supplement | |
| CA2015186A1 (en) | Nutrient composition | |
| NZ228710A (en) | Modified "echistatin" and anti-clotting pharmaceutical composition | |
| AU8188087A (en) | Variants of hirudin, their use and their preparation | |
| AU2670495A (en) | Ifn-beta liquid formulations | |
| AU624079B2 (en) | Novel fluorinated derivatives of amino acids usable more particularly as surfactants or cosurfactants and preparations for biomedical use incorporating these derivatives | |
| AU6406590A (en) | Porcine lactoferrin amino acid and cdna sequence | |
| AU8375891A (en) | Antioxidant system based on a basic amino acid in combination with a tocopherol or derivative thereof and a nonthiolated polypeptide, and compositions containing the same | |
| HU9402648D0 (en) | 3,4-dioxo-1-cyclobuten-1-yl-substituted (indolyl-alkyl)-pyridine- and -pyrimidine derivatives and antimigraine composition containing them as active componens | |
| MD1714G2 (ro) | Compoziţie terapeutică în formă de sirop, conţinând N-acetilcisteină | |
| CA2168570A1 (en) | Use of growth hormone for increasement of concentration of gh, igf-i and igfbp-3 in cerebrospinal fluid | |
| AU2557288A (en) | Synergistic antifungal protein and compositions containing same | |
| CA2153071A1 (en) | Derivatized calcitonins | |
| EP0292302A3 (en) | Human splenin | |
| CA2247998A1 (en) | Fragments of cr1 and their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |